Unicycive Therapeutics Stock Price Prediction
| UNCY Stock | USD 0.48 0.05 9.43% |
Oversold Vs Overbought
65
Oversold | Overbought |
EPS Estimate Next Quarter (0.18) | EPS Estimate Current Year (0.73) | EPS Estimate Next Year (0.20) | Wall Street Target Price 5.25 | EPS Estimate Current Quarter (0.19) |
Using Unicycive Therapeutics hype-based prediction, you can estimate the value of Unicycive Therapeutics from the perspective of Unicycive Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Unicycive Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Unicycive because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Unicycive Therapeutics after-hype prediction price | USD 0.49 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Unicycive |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Unicycive Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Unicycive Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Unicycive Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Unicycive Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Unicycive Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Unicycive Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Unicycive Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Unicycive Therapeutics' historical news coverage. Unicycive Therapeutics' after-hype downside and upside margins for the prediction period are 0.02 and 6.35, respectively. We have considered Unicycive Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Unicycive Therapeutics is extremely dangerous at this time. Analysis and calculation of next after-hype price of Unicycive Therapeutics is based on 3 months time horizon.
Unicycive Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Unicycive Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Unicycive Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Unicycive Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.91 | 5.86 | 0.01 | 0.23 | 8 Events / Month | 5 Events / Month | In about 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.48 | 0.49 | 2.08 |
|
Unicycive Therapeutics Hype Timeline
Unicycive Therapeutics is at this time traded for 0.48. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.23. Unicycive is forecasted to increase in value after the next headline, with the price projected to jump to 0.49 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 2.08%, whereas the daily expected return is at this time at 0.91%. The volatility of related hype on Unicycive Therapeutics is about 2359.73%, with the expected price after the next announcement by competition of 0.25. Unicycive Therapeutics currently holds 811 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next forecasted press release will be in about 8 days. Check out Unicycive Therapeutics Basic Forecasting Models to cross-verify your projections.Unicycive Therapeutics Related Hype Analysis
Having access to credible news sources related to Unicycive Therapeutics' direct competition is more important than ever and may enhance your ability to predict Unicycive Therapeutics' future price movements. Getting to know how Unicycive Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Unicycive Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CGEM | Cullinan Oncology LLC | 1.25 | 9 per month | 3.72 | (0.04) | 6.13 | (5.68) | 14.90 | |
| AVTE | Aerovate Therapeutics | (0.02) | 3 per month | 2.14 | 0.15 | 5.58 | (3.86) | 19.11 | |
| GPCR | Structure Therapeutics American | (2.65) | 9 per month | 2.71 | 0.02 | 8.03 | (4.47) | 21.24 | |
| LYRA | Lyra Therapeutics | (0.03) | 4 per month | 0.00 | (0.04) | 7.69 | (8.00) | 23.21 | |
| GOSS | Gossamer Bio | (0.02) | 6 per month | 2.25 | (0.01) | 6.06 | (4.17) | 16.84 | |
| INBX | Inhibrx | (0.02) | 6 per month | 1.83 | 0.15 | 6.22 | (3.38) | 16.75 |
Unicycive Therapeutics Additional Predictive Modules
Most predictive techniques to examine Unicycive price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Unicycive using various technical indicators. When you analyze Unicycive charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Unicycive Therapeutics Predictive Indicators
The successful prediction of Unicycive Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Unicycive Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Unicycive Therapeutics based on analysis of Unicycive Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Unicycive Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Unicycive Therapeutics's related companies. | 2010 | 2023 | 2024 (projected) | Dividend Yield | 0.0407 | 0.0366 | 0.0326 | Price To Sales Ratio | 8.55 | 31.54 | 16.04 |
Story Coverage note for Unicycive Therapeutics
The number of cover stories for Unicycive Therapeutics depends on current market conditions and Unicycive Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Unicycive Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Unicycive Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Unicycive Therapeutics Short Properties
Unicycive Therapeutics' future price predictability will typically decrease when Unicycive Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Unicycive Therapeutics often depends not only on the future outlook of the potential Unicycive Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Unicycive Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 24.5 M | |
| Cash And Short Term Investments | 9.7 M |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.